Omnicell (OMCL) | Stock Overview & Key Data
Omnicell Performance Comparison
Stock Range
Today's Range
Low: $30.46
High: $31.00
on October 6, 2025
52 Week Range
Low: $22.66
High: $55.75
on May 6, 2025
on October 30, 2024
All-Time High: $187.29 on November 22, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.5B
EPS
0.50
P/E Ratio (TTM)
61.90
Forward P/E
17.19
P/B Ratio
1.14
PEG Ratio
1.24
Div. Yield
N/A
ROE
1.87%
Beta
0.878
Debt to Equity
30.42
Financial Highlights
Profitability
Gross Margin
43.94%
Operating Margin
2.80%
Profit Margin
2.01%
Returns and Earnings
Return on Assets (TTM)
0.49%
Return on Equity (TTM)
1.87%
EBITDA
$102.7M
Net Income (TTM)
$23.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$24.78
Quarterly Revenue Growth (YoY)
5.00%
Quarterly Earnings Growth (YoY)
51.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Omnicell OMCL | 1.46B Small-cap | 0.59% | -5.60% | 5.53% | -3.42% | -31.14% | -28.39% | -58.34% | -62.99% |
| Veeva Systems VEEV | 48.56B Large-cap | 2.31% | 6.00% | 6.68% | 39.59% | 42.35% | 41.85% | 98.39% | -2.13% |
| Ge Healthcare GEHC | 34.95B Large-cap | 4.54% | -2.24% | 2.41% | 25.28% | -2.51% | -16.06% | 34.67% | 34.67% |
| Teladoc Health TDOC | 1.59B Small-cap | 4.51% | 9.31% | 6.20% | 18.53% | -9.98% | -6.85% | -63.00% | -96.13% |
| 10x Genomics TXG | 1.59B Small-cap | 11.46% | -9.26% | 6.04% | 66.75% | -10.92% | -22.26% | -50.59% | -92.28% |
| GoodRx Holdings GDRX | 1.57B Small-cap | 6.76% | 11.17% | -3.38% | 14.21% | 0.44% | -33.62% | -3.58% | -91.36% |
Ownership & Short Interest
Insider Ownership
1.79%
Institutional Ownership
104.53%
Shares Short
2M
Short Ratio
3.80
Short % of Shares Outstanding
6.19%
Average 10-Day Volume
350K
Average 90-Day Volume
489K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is OMCL's 52-week high and low?
- In the last 52 weeks, Omnicell reached a high of $55.75 (on October 30, 2024) and a low of $22.66 (on May 6, 2025).
- What is the market cap and P/E ratio for OMCL?
- Curious about Omnicell's size and valuation? Its market capitalization stands at 1.46B. When it comes to valuation, the P/E ratio (trailing twelve months) is 61.90, and the forward P/E (looking ahead) is 17.19.
- Does OMCL pay dividends? If so, what's the yield?
- As for dividends, Omnicell isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Omnicell's main competitors or similar companies to consider before investing?
When looking at Omnicell, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Veeva Systems
VEEV48.56B Healthcare Health Information Services 41.85% 98.39% Ge Healthcare
GEHC34.95B Healthcare Health Information Services -16.06% 34.67% Teladoc Health
TDOC1.59B Healthcare Health Information Services -6.85% -63.00% 10x Genomics
TXG1.59B Healthcare Health Information Services -22.26% -50.59% GoodRx Holdings
GDRX1.57B Healthcare Health Information Services -33.62% -3.58% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Omnicell Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Omnicell's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 1.87%, the Debt to Equity ratio from the most recent quarter is 30.42, and its Gross Profit Margin stands at 43.94%.
- What is the recent revenue and earnings growth for OMCL?
- Looking at Omnicell's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.00%, and quarterly earnings saw a YoY growth of 51.00%.
- How much of OMCL stock is held by insiders and institutions?
- Wondering who owns Omnicell stock? Company insiders (like executives and directors) hold about 1.79% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 104.53%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.